Document Type
Article
Publication Date
1-1-2016
Abstract
Biological advances have radically expanded our insights into the underpinnings of health and disease. New knowledge has formed the substrate for translation-expedited in turn by the biotechnology and pharmaceutical industry into novel therapeutic solutions impacting the management of patients and populations. Indeed, this Bioinnovation Enterprise has become the dominant growth sector in drug development and the engine driving the translation of breakthrough therapies worldwide. This annual Therapeutic Innovations issue highlights recent exceptional advances by the Bioinnovation Enterprise in translating molecular insights in pathobiology into transformative therapies.
Recommended Citation
Waldman, Scott A. and Terzic, Andre, "Bioinnovation Enterprise: An engine driving breakthrough therapies." (2016). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 72.
https://jdc.jefferson.edu/petfp/72
PubMed ID
26785918
Comments
This article has been peer reviewed. It is the authors' final version prior to publication in Clinical Pharmacology and Therapeutics
Volume 99, Issue 1, January 2016, Pages 8-13.
The published version is available at DOI: 10.1002/cpt.272. Copyright © American Society for Clinical Pharmacology and Therapeutics